You are here: Industry Insights > gilead

News List

Gilead sets Covid-19 drug candidate remdesivir price at $390 per vial pharmaceutical-technology
June 30, 2020
Gilead Sciences has set the price of its investigational Covid-19 drug remdesivir at $390 per vial for the US and governments of other developed countries.
Gilead to buy 49.9 per cent stake in cancer drug developer for $275 million expresspharma
June 28, 2020
The drugmaker said it has also secured the right to acquire the rest of the drug developer for a $315 million option exercise fee.
Gilead Acquires Stake in Pionyr Immunotherapeutics contractpharma
June 24, 2020
Has an exclusive option to acquire the remainder of Pionyr pending Phase I results of Pionyr’s Myeloid Tuning therapies.
Gilead targets remdesivir supply for two million COVID-19 patients by year-end expresspharma
June 24, 2020
The company also said it hoped to start trials in August of an easier-to-use inhaled version of the medicine, currently administered only intravenously.
Gilead announces results from Phase 3 Trial of remdesivir in patients with moderate COVID-19 worldpharmanews
June 17, 2020
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia.
Zydus Cadila inks licensing pact with Gilead for remdesivir expresspharma
June 16, 2020
The licence is royalty-free until another pharma product or vaccine is approved for the treatment or prevention of COVID-19 by the USFDA or EMA or the WHO announcing the end of the public health emergency.
Singapore approves Gilead’s remdesivir to treat Covid-19 pharmaceutical-technology
June 15, 2020
Singapore’s Health Sciences Authority (HSA) has awarded conditional approval for Gilead Sciences Singapore’s experimental antiviral drug remdesivir, under the brand name Veklury, to treat adults with Covid-19.
Gilead’s remdesivir shows modest improvement in moderate COVID-19 patients expresspharma
June 03, 2020
Remdesivir, which is administered intravenously in hospital, is the first drug to show improvement in COVID-19 patients in formal clinical trials.
Gilead and Arcus Ink $2B Cancer Partnership contractpharma
June 01, 2020
To co-develop and co-commercialize next-generation cancer immunotherapies.
Gilead seeks marketing authorisation from CDSCO for remdesivir expresspharma
June 01, 2020
The medicine has been issued EUA by the US FDA to treat hospitalised coronavirus patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page